Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Raymond James Upgrades Revolution Medicines to Strong Buy, Raises Price Target to $48

Author: Benzinga Newsdesk | April 10, 2024 01:17pm
Raymond James analyst Laura Prendergast upgrades Revolution Medicines (NASDAQ:RVMD) from Outperform to Strong Buy and raises the price target from $36 to $48.

Posted In: RVMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist